BUTALAN Drug Patent Profile
Which patents cover Butalan, and when can generic versions of Butalan launch?
Butalan is a drug marketed by Lannett and is included in one NDA.
The generic ingredient in BUTALAN is butabarbital sodium. There is one drug master file entry for this compound. Additional details are available on the butabarbital sodium profile page.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for BUTALAN?
- What are the global sales for BUTALAN?
- What is Average Wholesale Price for BUTALAN?
Summary for BUTALAN
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Raw Ingredient (Bulk) Api Vendors: | 6 |
| Patent Applications: | 1,217 |
| DailyMed Link: | BUTALAN at DailyMed |
US Patents and Regulatory Information for BUTALAN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Lannett | BUTALAN | butabarbital sodium | ELIXIR;ORAL | 085880-001 | Approved Prior to Jan 1, 1982 | DISCN | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
